Opus Genetics initiates $40M ATM equity offering with Leerink Partners

Opus Genetics, Inc.

Entered into ATM equity sales agreement with Leerink Partners LLC for up to $40M in common stock.
Prior ATM program with JonesTrading terminated; $26.4M had been sold under that program.
Net proceeds for general corporate purposes, including preclinical studies and clinical trials.
Leerink receives 3% commission on gross sales; Company has broad discretion over proceeds use.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.